<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5776">
  <stage>Registered</stage>
  <submitdate>15/10/2015</submitdate>
  <approvaldate>15/10/2015</approvaldate>
  <nctid>NCT02579382</nctid>
  <trial_identification>
    <studytitle>A Study of the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated</studytitle>
    <scientifictitle>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2015-002017-30</secondaryid>
    <secondaryid>GS-US-283-1062</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Hepatitis B</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - TDF
Treatment: drugs - Vesatolimod
Treatment: drugs - Placebo

Placebo Comparator: TDF + placebo - TDF + placebo

Experimental: TDF + vesatolimod 1 mg - TDF + vesatolimod 1 mg

Experimental: TDF + vesatolimod 2 mg - TDF + vesatolimod 2 mg

Experimental: TDF + vesatolimod 4 mg - TDF + vesatolimod 4 mg


Treatment: drugs: TDF
300 mg tablets administered orally once daily

Treatment: drugs: Vesatolimod
Tablets administered orally once a week (every 7 days) for 12 doses

Treatment: drugs: Placebo
Placebo administered orally once a week (every 7 days) for 12 doses

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mean Change (Measured in log10 IU/mL) in Serum Hepatitis B Surface Antigen (HBsAg) from Baseline at Week 24</outcome>
      <timepoint>Baseline; Week 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportions of Participants with Hepatitis B e Antigen (HBeAg) Loss and Seroconversion at Week 24</outcome>
      <timepoint>Baseline; Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportions of Participants with Hepatitis B e Antigen (HBeAg) Loss and Seroconversion at Week 48</outcome>
      <timepoint>Baseline; Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportions of Participants with HBsAg Loss and Seroconversion at Week 24</outcome>
      <timepoint>Baseline; Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportions of Participants with HBsAg Loss and Seroconversion at Week 48</outcome>
      <timepoint>Baseline; Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Change (Measured in log10 IU/mL) in HBsAg from Baseline at Week 12</outcome>
      <timepoint>Baseline; Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean Change (Measured in log10 IU/mL) in HBsAg from Baseline at Week 48</outcome>
      <timepoint>Baseline; Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportions of Participants with a = 0.5 log10 IU/mL Decline in Serum HBsAg Titers from Baseline at Week 12</outcome>
      <timepoint>Baseline; Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportions of Participants with a = 0.5 log10 IU/mL Decline in Serum HBsAg Titers from Baseline at Week 24</outcome>
      <timepoint>Baseline; Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportions of Participants with a = 0.5 log10 IU/mL Decline in Serum HBsAg Titers from Baseline at Week 48</outcome>
      <timepoint>Baseline; Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportions of Participants with Hepatitis B Virus (HBV) DNA &lt; Lower Limit of Quantitation (LLOQ) at Week 24</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportions of Participants with Hepatitis B Virus (HBV) DNA &lt; Lower Limit of Quantitation (LLOQ) at Week 48</outcome>
      <timepoint>Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Participants Experiencing Virologic Breakthrough</outcome>
      <timepoint>Up to Week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Participants with Drug Resistance Mutations</outcome>
      <timepoint>Up to Week 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic (PK) Parameter: AUClast of Vesatolimod - AUClast is defined as the concentration of drug from time zero to the last observable concentration.</outcome>
      <timepoint>Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK Parameter: AUCinf of Vesatolimod - AUCinf is defined as the concentration of drug extrapolated to infinite time.</outcome>
      <timepoint>Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK Parameter: %AUCexp of Vesatolimod - %AUCexp is defined as the percentage of AUC extrapolated between AUClast and AUCinf.</outcome>
      <timepoint>Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK Parameter: Cmax of Vesatolimod - Cmax is defined as the maximum concentration of drug.</outcome>
      <timepoint>Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK Parameter: Clast of Vesatolimod - Clast is defined as the last observable concentration of drug.</outcome>
      <timepoint>Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK Parameter: Tmax of Vesatolimod - Tmax is defined as the time (observed time point) of Cmax</outcome>
      <timepoint>Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK Parameter: Tlast of Vesatolimod - Tlast is defined as the time (observed time point) of Clast.</outcome>
      <timepoint>Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK Parameter: T1/2 of Vesatolimod - T1/2 is defined as the estimate of the terminal elimination half-life of the drug.</outcome>
      <timepoint>Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK Parameter: CL/F of Vesatolimod - CL/F is defined as the apparent oral clearance following administration of the drug.</outcome>
      <timepoint>Predose, 0.5, 1, 2, 4, 6, 8, 10, 12, and 24 hours postdose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Adult males or females between the ages of 18-65

          -  Chronic HBV infection

          -  HBV DNA = 2000 IU/mL at screening

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Extensive bridging fibrosis or cirrhosis

          -  Received oral antiviral treatment for HBV or prolonged therapy with immune-modulators
             or biologics within 3 months of screening

          -  Co-infection with hepatitis C virus (HCV), HIV or hepatitis D virus (HDV)

          -  Chronic liver disease other than HBV

          -  Lactating or pregnant females or those that wish to become pregnant during the course
             of the study

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>10/11/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>192</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Kowloon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>San Giovanni Rotondo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Dalin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objectives of this study are to evaluate the safety, tolerability, and efficacy
      of vesatolimod (formerly GS-9620) in adults with chronic hepatitis B (CHB) infection who are
      currently not being treated.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02579382</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gilead Study Director</name>
      <address>Gilead Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>